What is the main business of Solinea Pharma?

The main business activity of Solinea Pharma focuses on office administrative service activities.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on October 12, 2015.

Where is the headquarters located?

The headquarters is located at: ul. Szafranowa 6, 21-003 Elizówka.

Who is on the management board?

The management board includes Mariusz Tomasz Trus (President of the Management Board).

What is the share capital?

The share capital of the company is PLN 5,000 (approx. $1,351).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.

How much revenue was generated?

In 2024, the company generated total revenue of $935,243, representing an increase of 7.2% compared to 2023.

Is the company profitable?

Yes, the company recorded a net profit of $28,489 in 2024, meaning the company decreased its profit by 0.5%.

Which cost dominates operating expenses?

The largest operating cost category falls under employee remuneration. This category amounted to $629,072 in 2024, representing 69% of all operating expenses.

Solinea Pharmasp. z o.o.

Office administrative service activities

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2015-10-12

Share capital

5,000.00 PLN

Activity description

Solinea Pharma is a Polish pharmaceutical company that develops and supplies products for the healthcare sector. Its portfolio includes more than 150 products, and the company has 20 years of experience and works with over 1,500 partners.

Registered address

ul. Szafranowa 6, 21-003 Elizówka, Poland

Website

solinea.pl

Phone

Social media

Electronic delivery address

AE:PL-32263-28511-RTGEC-11

Financials

Revenue history (in k)

Filing timeliness

3 of 6 financial statements were filed late (the longest delay 436 days for 2022).

202513/07/2026
202411/07/2025
202323/09/2024
202223/09/2024
202114/10/2022
202030/09/2021

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 1.00mMedianUSD 49.58kAverageUSD 1.46m

Net profit

This companyUSD 29.71kMedianUSD 2.10kAverageUSD 196.41k

Operating costs

This companyUSD 970.82kMedianUSD 44.02kAverageUSD 1.15m

Assets

This companyUSD 246.38kMedianUSD 40.01kAverageUSD 9.73m

News

2025-08-26

Fertistim ovu – patented Caronositol FertilityⓇ formula recommended for women with PCOS and fertility support

2024-12-02

Muconasin – over-the-counter nasal spray with N-acetylcysteine

2024-10-15

What is Physiomanna Baby? When and how to use Physiomanna Baby

2024-06-29

Fertistim for women – inositol sachets for PCOS, insulin resistance, and prolonged attempts to conceive

2023-07-17

Ectodose inhalation solution with ectoine over-the-counter, new packaging

Industry

Office administrative service activities (82.11.Z)Primary

Offer

Prescription medicines
Over-the-counter medicines
Dietary supplements
Medical devices
Cosmetics

Website technology

Website

WordPress

Analytics and marketing

Google Analytics
Google Tag Manager

Authorized Representatives

Katarzyna Lidia Grosner – Attorney-in-fact (sole)

Mariusz Tomasz Trus – President of the Management Board

Manner of representation

Each member of the management board is authorized to make declarations on behalf of the company independently.

Ownership

Owner	Shares	Share value	Stake
Solpharma Plus sp. z o.o.	50	$1,350.62	100%

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2015-10-30.

ING Bank Śląski
23 1050 1953 1000 0090 3074 9809

Debt

No entries in the National Debtors Register (KRZ).

Public aid

5 public aid cases recorded, with a total value of $85,866.

Grant date	Purpose	Gross amount	Granting body
Sep 20, 2020	Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts	$5,752$5,752	Prezes Zakładu Ubezpieczeń Społecznych
May 30, 2020	Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts	$5,915$5,915	Prezes Zakładu Ubezpieczeń Społecznych
May 30, 2020	Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts	$5,082$5,082	Prezes Zakładu Ubezpieczeń Społecznych

Competitors

Name	Revenue	Website
Solinea Pharmaceuticalssp. z o.o.	$1,051,452.37	solinea.pl
Contact PharmS.K.A.	$825,293.63	contactpharm.pl
Inno4medsp. z o.o.	$140,269.98	inno4med.pl

Change history

Date	Event
2023-08-09	Address change (65, 21-003, Elizówka → Ul. Szafranowa 6, 21-003, Elizówka)
2021-03-17	Address change (65/Hala L, 21-003, Elizówka → 65, 21-003, Elizówka)
2020-09-14	Address change (65/Hala I, 21-003, Elizówka → 65/Hala L, 21-003, Elizówka)
2015-10-12	Entered in the register

FAQ

Last updated: 2026-10-07